Autolus reiterates $120M–$135M AUCATZYL revenue target for 2026 while expanding pivotal trial pipeline

What: Autolus reiterates AUCATZYL revenue target of $120M–$135M for 2026.
Why: The company is expanding its pivotal trial pipeline to support the growth of AUCATZYL.
Signal: Strong revenue growth is expected for AUCATZYL, driven by expanding trial pipeline.
Target: Autolus aims to achieve $120M–$135M in AUCATZYL revenue by the end of 2026.
Risk: Expansion of pivotal trial pipeline may pose operational and regulatory risks for Autolus.